Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cytisine vs Nicotine Replacement Therapy in Chronic Kidney Disease Smokers
2023-509235-39-00Phase 4Authorised
- Sponsor
- Maria Skłodowska-Curie National Research Institute of Oncology
- Start
- Mar 2024
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of cytisinicline in nicotine dependence (2 arms), sponsored by Maria Skłodowska-Curie National Research Institute of Oncology. Planned start Mar 2024; status: authorised.
02
Drugs
cytisinicline
03
Conditions
nicotine dependence
Beyond the preview
Go deeper on 2023-509235-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509235-39-00.